Perlecan is essential for cartilage and cephalic development

被引:401
作者
Arikawa-Hirasawa, E
Watanabe, H
Takami, H
Hassell, JR
Yamada, Y [1 ]
机构
[1] Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA
[2] Shriners Hosp Crippled Children, Tampa, FL 33612 USA
关键词
D O I
10.1038/15537
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Perlecan, a large, multi-domain, heparan sulfate proteoglycan originally identified in basement membrane, interacts with extracellular matrix proteins, growth factors and receptors, and influences cellular signalling. Perlecan is present in a variety of basement membranes and in other extracellular matrix structures. We have disrupted the gene encoding perlecan (Hspg2) in mice. Approximately 40% of Hspg2(-/-) mice died at embryonic day (E) 10.5 with defective cephalic development. The remaining Hspg2(-/-) mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities. Only 6% of Hspg2(-)mice developed both ex-encephaly and chondrodysplasia. Hspg2(-/-) cartilage showed severe disorganization of the columnar structures of chondrocytes and defective endochondral ossification. Hspg2(-/-) cartilage matrix contained reduced and disorganized collagen fibrils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure. In Hspg2(-/-) cartilage, proliferation of chondrocytes was reduced and the prehypertrophic zone was diminished. The abnormal phenotypes of the Hspg2(-/-) skeleton are similar to those of thanatophoric dysplasia (TD) type I, which is caused by activating mutations in FGFR3 (refs 7-9), and to those of Fgfr3 gain-of-function mice. Our findings suggest that these molecules affect similar signalling pathways.
引用
收藏
页码:354 / 358
页数:5
相关论文
共 33 条
[1]   IMMUNOSTAINING OF SKELETAL AND CARDIAC-MUSCLE SURFACE-MEMBRANE WITH ANTIBODY AGAINST DUCHENNE MUSCULAR-DYSTROPHY PEPTIDE [J].
ARAHATA, K ;
ISHIURA, S ;
ISHIGURO, T ;
TSUKAHARA, T ;
SUHARA, Y ;
EGUCHI, C ;
ISHIHARA, T ;
NONAKA, I ;
OZAWA, E ;
SUGITA, H .
NATURE, 1988, 333 (6176) :861-863
[2]   Mouse models for extracellular matrix diseases [J].
Aszódi, A ;
Pfeifer, A ;
Wendel, M ;
Hiripi, L ;
Fässler, R .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1998, 76 (3-4) :238-252
[3]   Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA [J].
Aviezer, D ;
Iozzo, RV ;
Noonan, DM ;
Yayon, A .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (04) :1938-1946
[4]   PERLECAN, BASAL LAMINA PROTEOGLYCAN, PROMOTES BASIC FIBROBLAST GROWTH FACTOR-RECEPTOR BINDING, MITOGENESIS, AND ANGIOGENESIS [J].
AVIEZER, D ;
HECHT, D ;
SAFRAN, M ;
EISINGER, M ;
DAVID, G ;
YAYON, A .
CELL, 1994, 79 (06) :1005-1013
[5]   Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein [J].
Chuang, PT ;
McMahon, AP .
NATURE, 1999, 397 (6720) :617-621
[6]   Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 [J].
Colvin, JS ;
Bohne, BA ;
Harding, GW ;
McEwen, DG ;
Ornitz, DM .
NATURE GENETICS, 1996, 12 (04) :390-397
[7]   Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses [J].
Delezoide, AL ;
LasselinBenoist, C ;
LegeaiMallet, L ;
Brice, P ;
Senee, V ;
Yayon, A ;
Munnich, A ;
Vekemans, M ;
Bonaventure, J .
HUMAN MOLECULAR GENETICS, 1997, 6 (11) :1899-1906
[8]   Fibroblast growth factor receptor 3 is a negative regulator of bone growth [J].
Deng, CX ;
WynshawBoris, A ;
Zhou, F ;
Kuo, A ;
Leder, P .
CELL, 1996, 84 (06) :911-921
[9]  
Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO
[10]  
2-H